

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR ISSUE TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA.



(Please scan this QR code to view the Prospectus)

TAKYON NETWORKS LIMITED

CIN: U72300UP2015PTC070649

Our Company was originally incorporated as a Private Limited Company under the name “Takyon Networks Private Limited” on May 12, 2015 under the provisions of the Companies Act, 2013 with the Registrar of Companies, Uttar Pradesh, Kanpur with CIN: U72300UP2015PTC070649. Thereafter, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extraordinary General Meeting, held on May 30, 2024 and consequently the name of our Company was changed from “Takyon Networks Private Limited” to “Takyon Networks Limited” vide a fresh certificate of incorporation dated August 07, 2024, issued by the Registrar of Companies, Central Processing Centre. The Corporate Identification Number of our Company is U72300UP2015PLC070649.

Registered Office: CP 37, Viraj Khand Gomti Nagar, Lucknow – 226 010, Uttar Pradesh, India
Tel No: +91-0522-6656617; **E-mail:** cs@takyon.co.in; **Website:** www.takyon.co.in
CIN: U72300UP2015PLC070649 ; **Contact Person:** Pooja Sharma, Company Secretary & Compliance Officer

OUR PROMOTER: MANISH KUMAR SHARMA AND NEERAJ KUMAR

“THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE (BSE SME).”

We are in the business of providing comprehensive networking and IT infrastructure solutions, serving a diverse range of clients, including government agencies and corporate enterprises. Our services include IT networking solutions, data center solutions, IT security and surveillance, cloud and managed services. We also issue maintenance and support services to our clients through formal contracts, providing expert technical support.

BASIS OF ALLOTMENT

INITIAL PUBLIC ISSUE OF UPTO 37,92,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH (THE “EQUITY SHARES”) OF TAKYON NETWORKS LIMITED (“OUR COMPANY” OR “THE ISSUER”) AT AN ISSUE PRICE OF ₹54 PER EQUITY SHARE (INCLUDING SHARE PREMIUM OF ₹44 PER EQUITY SHARE) FOR CASH, AGGREGATING UP TO ₹2,047.68 LAKHS (“PUBLIC ISSUE”) OUT OF WHICH 1,92,000 EQUITY SHARES OF FACE VALUE OF ₹10 EACH, AT AN ISSUE PRICE OF ₹54 PER EQUITY SHARE FOR CASH, AGGREGATING ₹103.68 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE “MARKET MAKER RESERVATION PORTION”) THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 36,00,000 EQUITY SHARES OF FACE VALUE OF ₹10 EACH, AT AN ISSUE PRICE OF ₹54 PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹1,944.00 LAKHS IS HEREIN AFTER REFERRED TO AS THE “NET ISSUE”. THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.48% AND 25.14% RESPECTIVELY OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY

THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10 AND THE ISSUE PRICE IS ₹ 54 EACH. THE ISSUE PRICE IS 5.4 TIMES OF THE FACE VALUE OF THE EQUITY SHARE
ANCHOR INVESTOR ISSUE PRICE: ₹ 54 PER EQUITY SHARE. THE ISSUE PRICE IS 5.4 TIMES OF THE FACE VALUE

BID/ISSUE PERIOD

ANCHOR INVESTOR BIDDING DATE WAS: JULY 29, 2025

BID/ISSUE OPENED ON: JULY 30, 2025

BID/ISSUE CLOSED ON: AUGUST 01, 2025

RISKS TO INVESTORS:

For details refer to section titled “Risk Factors” on page no. 23 of the Prospectus
Risk to investors summary description of key risk factors based on materiality

- a) We are heavily reliant on a few vendors/ suppliers and we typically do not enter into long term contracts or arrangements with our vendors. Any loss of such vendors / suppliers or any increase in the price will have a material adverse impact on our business and our revenue.
- b) Our financial condition could be materially and adversely affected if we fail to secure new government and PSU projects.
- c) A Significant proportion of our orders are from government related entities which award the contract through the process of tender. Tenders, typically, are awarded to the lower bidder once all other eligibility criteria are met. Our performance could be adversely affected if we are not able to successfully bid for these contracts or required to lower our bid value.
- d) We depend on few Customer Industries for majority of our revenue from operations. Loss of customers in these Customer industries may result in an adverse effect on our business, revenue from operations and financial conditions.
- e) Any increase in the cost of, or a shortfall in the supply of IT Equipment's, may adversely affect the pricing and supply of our products and have an adverse effect on our business, results of operations and financial condition.
- f) There are certain discrepancies/errors noticed in some of our corporate records relating to forms filed with the Registrar of Companies and other provisions of Companies Act, 2013. Some of our corporate records are not traceable. Any penalty or action taken by any regulatory authorities in future, for non-compliance with provisions of corporate and other law could impact the reputation and financial position of the Company to that extent.
- g) If we cannot attract and retain highly-skilled IT professionals, our ability to obtain, manage and staff new projects and to continue to expand existing projects may result in loss of revenue and an inability to expand our business.
- h) Our current order book value is not necessarily indicative of future growth. Further, some of the orders that constitute our current order could be cancelled, put in abeyance, delayed, or not paid for by our customers, which could adversely affect our financial condition.
- i) We have working capital requirements. If we experience insufficient cash flows to make required payments on our debt or fund working capital requirements, there may be an adverse effect on our results of operations.
- j) The IT solutions market is highly competitive and our competitors may have advantages that could allow them to compete more effectively than we do to secure customer contracts. Any failure to compete effectively could have a material adverse effect on our business, financial condition and results of operations.
- k) The Merchant Banker associated with the Issue has handled 66 public issues in the past three years, out of which 2 SME Issues were closed below the Issue Price on listing date.

Name of BRLM	Total Issue		Issue closed below IPO Price on listing date
	Mainboard	SME	
Hem Securities Limited	2	64	2 (SME)

PROPOSED LISTING: August 06, 2025*

The Issue was being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”) read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue was available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs”, the “QIB Portion”), Our Company in consultation with the Book Running Lead Manager has allocated up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations (“Anchor Investor Portion”). Further, not less than 15% of the Net Issue was made available for allocation on a proportionate basis to Non-Institutional Bidders (out of which one third was reserved for applicants with an application size of more than two lots and up to such lots equivalent to not more ₹ 10,00,000 and two-thirds was reserved for applicants with application size of more than ₹ 10,00,000) and not less than 35% of the Net Issue was made available for allocation to Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) were required to mandatorily utilise the Application Supported by Blocked Amount (“ASBA”) process providing details of their respective ASBA accounts, and UPI ID in case of Individual Investors using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors were not permitted to participate in the Issue through the ASBA process. For details, see “*Issue Procedure*” beginning on page 201 of the Prospectus.

The investors are advised to refer to the Prospectus for the full text of the Disclaimer clause pertaining to BSE. For the purpose of this Issue, the designated Stock Exchange will be the BSE Limited. The trading is proposed to be commenced on or before August 06, 2025*

*Subject to the receipt of listing and trading approval from the BSE (“**BSE SME**”).

SUBSCRIPTION DETAILS

The bidding for Anchor Investors opened and closed on July 29, 2025. The Company received 5 Anchor Investors applications for 10,68,000 Equity Shares. The Anchor Investor Allocation price was finalized at ₹54/- per Equity Share. A total of 10,68,000 Equity Shares were allotted under the Anchor Investors portion aggregating to ₹ 5,76,72,000/-.

The Issue (excluding Anchor Investors Portion) received 11,403 Applications for 7,24,48,000 Equity Shares (before considering invalid bids, Other than RC10 Transaction declined by Investors, RC10 Mandate not accepted by Investors and Withdrawal/ Cancelled Bids reported by SCSB and rejections) resulting 26.60 times subscription (including reserved portion of market maker and excluding anchor investor portion). The details of the Applications received in the Issue from various categories are as under (after rejections):

Detail of the Applications Received (excluding Anchor Investors Portion):

Sr. No.	Category	Number of Applications	No. of Equity Shares applied	Equity Shares Reserved as per Prospectus	No. of times Subscribed	Amount (Rs.)
1	Qualified Institutional Bidders (excluding Anchor Investors)	6	94,66,000	7,14,000	13.26	3,85,56,000.00
2	Non Institutional Investors - above Rs. 2 Lakhs and Upto Rs. 10 Lakhs	635	41,52,000	1,86,000	37.08	1,00,44,000.00
3	Non Institutional Investors -Above Rs. 10 Lakhs	739	1,60,96,000	3,60,000		1,94,40,000.00
4	Individual Investors	6327	2,53,08,000	12,72,000	19.90	6,86,88,000.00
5	Market Maker	1	1,92,000	1,92,000	1.00	1,03,68,000.00
TOTAL		7,708	5,52,14,000	27,24,000	20.26	14,70,96,000.00

1) Allotment to Individual Investors (After Rejections):

The Basis of Allotment to the Individual Investors, who have Bid at the Issue Price of ₹ 54 per Equity Share, was finalized in consultation with BSE. The category has been subscribed to the extent of 19.90 times. The total number of Equity Shares Allotted in this category is 12,72,000 Equity Shares to 318 successful applicants. The details of the Basis of Allotment of the said category are as under:

No. of Shares Applied for (Category wise)	No. of Applications Received	% of Total	Total No. of Shares Applied	% to Total	No. of Equity Shares Allotted per Applicant	Ratio	Total No. of shares allocated/ allotted
4,000	6,327	100.00	2,53,08,000	100.00	4000	106 2109	12,72,000

2) Allotment to Non-Institutional Investors (More than ₹ 200,000 and up to ₹ 1,000,000) (After Rejections):

The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of ₹ 54 per Equity Share was finalized in consultation with BSE. The category has been subscribed to the extent of 22.32 times (after rejection). The total number of Equity Shares Allotted in this category is 186000 Equity Shares to 31 successful applicants. The details of the Basis of Allotment of the said category are as under:

S. No	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No of equity shares	Ration of allottees to applicants	Total No. of shares allocated/allotted
1	6,000	553	87.09	33,18,000	79.91	6,000	27 553	1,62,000
2	8,000	51	8.03	4,08,000	9.83	6,000	2 51	12,000
3	10,000	9	1.42	90,000	2.17	6,000	0 9	0
4	12,000	6	0.94	72,000	1.73	6,000	0 6	0
5	14,000	5	0.79	70,000	1.69	6,000	0 5	0
6	16,000	2	0.31	32,000	0.77	6,000	0 2	0
7	18,000	9	1.42	1,62,000	3.90	6,000	0 9	0
All applicants from Serial no 3 to 7 for minimum allotment of 6000 shares						6,000	2 31	12,000
TOTAL		635	100.00	41,52,000	100.00			1,86,000

3) Allotment to Non-Institutional Investors (More than ₹ 1,000,000)

The Basis of Allotment to the Non-Institutional Investors, who have bid at the Issue Price of ₹ 54 per Equity Share was finalized in consultation with BSE. The category has been subscribed to the extent of 44.71 times (after rejection). The total number of Equity Shares Allotted in this category is 360,000 Equity Shares to 60 successful applicants. The details of the Basis of Allotment of the said category are as under:

S.No	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each category	% to total	No of equity shares	Ration of allottees to applicants	Total No. of shares allocated/allotted
1	20,000	709	95.94	1,41,80,000	88.10	6,000	58 709	3,48,000
2	22,000	15	2.03	3,30,000	2.05	6,000	1 15	6,000
3	24,000	8	1.08	1,92,000	1.19	6,000	1 8	6,000
4	26,000	1	0.14	26,000	0.16	6,000	0 1	0
5	30,000	1	0.14	30,000	0.19	6,000	0 1	0
6	36,000	1	0.14	36,000	0.22	6,000	0 1	0
7	1,08,000	1	0.14	1,08,000	0.67	6,000	0 1	0
8	1,20,000	1	0.14	1,20,000	0.75	6,000	0 1	0
9	1,50,000	1	0.14	1,50,000	0.93	6,000	0 1	0
10	9,24,000	1	0.14	9,24,000	5.74	6,000	0 1	0
TOTAL		739	100.00	1,60,96,000	100.00			3,60,000

i) Average cost of acquisition of Equity Shares held by the Individual Promoters are

Sr. No.	Name of the Promoters	No. of share held	Average cost of Acquisition (in ₹)
1.	Manish Kumar Sharma	52,64,700	3.33
2.	Neeraj Kumar	52,64,700	3.33

and the Issue Price at the upper end of the Price Band is Rs. 54 per Equity Share.

m) The Price/ Earnings ratio based on Diluted EPS for Fiscal 2025 for the company at the upper end of the Price Band is 8.17.

n) Weighted Average Return on Net worth for Fiscals 2025, 2024, and 2023 is 18.09%.

o) The Weighted average cost of acquisition of all Equity Shares transacted in the last one year, 18 months and three years from the date of Prospectus is as given below:

Period	Weighted Average Cost of Acquisition (in Rs.)	Upper end of the Price Band (Rs. 54) is 'X' times the weighted Average cost of Acquisition	Range of acquisition price: Lowest Price – Highest Price (in Rs.)
Last one year, 18 months & three years preceding the date of the Prospectus.	0.00	0.00	0.00

p) The Weighted average cost of acquisition compared to Floor Price and Cap Price.

Types of transactions	Weighted Average Cost of Acquisition (₹ per Equity Shares)	Floor price (i.e. ₹ 51/-)	Cap price (i.e. ₹ 54/-)
Weighted average cost of acquisition of primary/new issue.	NA^	NA^	NA^
Weighted average cost of acquisition for secondary sale/acquisition.	NA^^	NA^^	NA^^
Weighted average cost of acquisition of primary issuances / secondary transactions.	0.00	0.00 times	0.00 times

Note:

^There were no primary/ new issues of shares (equity/ convertible securities) other than Equity Shares issued pursuant to a bonus issue on May 03, 2024 in last 18 months prior to the date of Prospectus.

^^There were no secondary sales/acquisition of shares (equity/ convertible securities), in last 18 months from the date of Prospectus.

Final Demand:

A summary of the final demand as per BSE as on the Bid/ Issue Closing Date at different Bid prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Share Total	Cumulative % of Total
1	51	218,000	0.30%	2,18,000	0.30%
2	52	96,000	0.13%	3,14,000	0.43%
3	53	88,000	0.12%	4,02,000	0.55%
4	54	7,20,46,000	99.45%	7,24,48,000	100.00%
TOTAL		7,24,48,000	100.00%		

The Basis of Allotment was finalized in consultation with the designated Stock Exchange, being BSE Limited (“**BSE SME**”) on August 04, 2025.

No. of Shares Applied for (Category wise)	No. of Applications received	% to total	Total No. of Equity Shares applied in this Category	% of total	No. of Equity Shares allocated/ allotted per Applicant	Ratio	Total No. of shares allocated/allotted
1,92,000	1	100.00	1,92,000	100.00	1,92,000	FIRM	1,92,000

5) Allotment to QIBs excluding Anchor Investors (After Rejections):

Allotment to QIBs, who have bid at the Issue Price of ₹ 54/- per Equity Share has been done on a proportionate basis in consultation with BSE. This category has been subscribed to the extent of 13.26 times of QIB portion. The total number of Equity Shares allotted in the QIB category is 7,14,000 Equity Shares, which were allotted to 6 successful Applicants.

Category	FI'S/BANK'S	MF'S	IC'S	NBFC'S	AIF	FPC/FII	Others	Total
QIB	-	-	-	4,08,000	2,90,000	16,000	0	7,14,000

Continued on next page

Continued from previous page

6) Allotment to Anchor Investors (After Technical Rejections):
The Company in consultation with the BRLM has allocated 10,68,000 Equity Shares to 5 Anchor Investors at the Anchor Investor Issue Price of ₹ 54 per Equity Shares in accordance with the SEBI (ICDR) Regulations. This represents 59.93% of the QIB Category.

CATEGORY	FIS/BANKS	MF'S	IC'S	NBFC'S	AIF	FPI/FPC	VC'S	TOTAL
ANCHOR	-	-	-	1,86,000	8,82,000	-	-	10,68,000

The Board of Directors of our Company at its meeting held on August 04, 2025 has taken on record the basis of allotment of Equity Shares approved by the

INVESTORS, PLEASE NOTE

The details of the allotment made have been hosted on the website of the Registrar to the Issue, Cameo Corporate Services Limited at the website: www.cameoindia.com

TRACK RECORD OF BOOK RUNNING LEAD MANAGER: The BRLM associated with the Issue has handled 66 Public Issues in the past three years, out of which 2 issues were closed below the Issue/Offer Price on listing date:

Name of BRLM	Total Issue		Issue closed below IPO Price on listing date
	Mainboard	SME	
Hem Securities Limited	2	64	2 (SME)

All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole Bidder Serial number of the ASBA form, number of Equity Shares bid for, Bidder DP ID, Client ID, PAN, date of submission of the Bid cum Application Form, address of the Bidder, the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and copy of the Acknowledgment Slip received from the Designated Intermediary and payment details at the address given below:




Cameo Corporate Services Limited
Address: Subramanian Building No.1, Club House Road, Chennai – 600 002, Tamil Nadu, India.
Tel No.: +91-44-40020700/28460390; **Email:** ipo@cameoindia.com; **Website:** www.cameoindia.com;
Tel.: 0265 6637000
E-mail: apl.investors@alembic.co.in
Website: www.alembicpharmaceuticals.com

On behalf of the Board of Directors
Takyon Networks Limited
Sd/-
Pooja Sharma
Company Secretary and Compliance Officer

Place: Lucknow
Date: August 05, 2025

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF TAKYON NETWORKS LIMITED
Disclaimer: Takyon Networks Limited has filed the Prospectus with the RoC on August 04, 2025 and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of the BRLM, Hem Securities Limited at www.hemsecurities.com and the Company at: www.takyon.co.in and shall also be available on the website of the BSE and SEBI. Investors should note that investment in Equity Shares involves a high degree of risk and for details relating to the same, please see **“Risk Factors”** beginning on page 23 of the Prospectus.
The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the **“Securities Act”**) or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being issued and sold outside the United States in 'offshore transactions' in reliance on Regulation under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public issuing in the United States.



BirlaNu Limited
(Formerly known as HIL Limited)
CIN: L74999TG1955PLC000656
Registered Office: Office No. 1 & 2, L7 Floor, SLN Terminus, Survey No. 133, Beside Botanical Garden, Gachibowli, Telangana, Hyderabad - 500032
Ph. No.: +91 40 68249000 | cs@birlanu.com | <https://birlanu.com/>

SPECIAL WINDOW FOR RE-LODGE
MENT OF TRANSFER REQUESTS OF PHYSICAL SHARES

Notice is hereby given to the Shareholders of BirlaNu Limited that in terms of SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 dated July 2, 2025, a Special Window has been opened from July 7, 2025 to January 6, 2026, for re-lodgement of transfer requests that were lodged prior to April 1, 2019, but were rejected/returned/not attended to due to deficiency in the documents/process/or otherwise.

All such transfer requests duly rectified and re-lodged on or before January 6, 2026 will be processed through the transfer-cum-demat mode, i.e., the shares will be issued only in dematerialised form after transfer. The lodger(s) must have a demat account and provide the Client Master List (CML) along with the transfer documents, share certificate(s) and other necessary document(s) while lodging the documents for transfer with our RTA.

Eligible shareholders are requested to submit their transfer requests to the Company's Registrar and Share Transfer Agent (RTA), i.e., Venture Capital and Corporate Investments Private Limited, "AURUM", 4th & 5th Floor, Plot No.57, Jayabheth Enclave Phase-II, Gachibowli, Hyderabad – 500032, Phone: +91-40-2381847/576 Email: investor.relations@vccpi.com or contact the Company at cs@birlanu.com for further assistance.

For BirlaNu Limited
Sd/-
Nidhi Bisaria
Company Secretary & Compliance Officer

Place: New Delhi
Date: August 5, 2025



Chemcon Speciality Chemicals Limited
(AN ISO 9001:2015 and ISO 14001:2015 Certified Company)
Regd. Office: Block No. 355, Manjusar Kungad Road, Village-Manjusar, Taluka-Savli, Vadodara - 391775, Gujarat.
Email: investor.relations@csopl.com | **Website:** www.csopl.com | **Tel:** 0265-2981195 | **CIN:** L24231GJ1988PLC011652

EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025
(Rs. in Lacs)

Particulars	Quarter Ended		Year Ended	
	30-06-25	31-03-25	30-06-24	31-03-25
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
I Total income from operations	5,723.49	5,807.20	4,928.60	22,169.45
II Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	843.03	539.77	736.60	3,314.64
III Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	843.03	539.77	736.60	3,314.64
IV Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	638.71	394.60	536.88	2,445.21
V Total Comprehensive Income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	633.66	385.18	533.29	2,425.01
VI Equity Share Capital	3,663.07	3,663.07	3,663.07	3,663.07
VII Other Equity	-	-	-	46,402.79
VIII Earning Per equity Share: (Face Value of Rs 10/- each) (For the period not annualised)				
Basic (in Rs.)	1.74	1.08	1.47	6.68
Diluted (in Rs.)	1.74	1.08	1.47	6.68

Notes :
1. The above is an extract of the detailed format of Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Company's website at www.csopl.com and the Stock Exchange's Website at www.bseindia.com and www.nseindia.com.

By order of the Board
For Chemcon Speciality Chemicals Limited
Sd/-
Kamalkumar Rajendra Aggarwal
Chairman & Managing Director
DIN: 00139199

Place : Vadodara
Date : August 5, 2025

RISHI TECHTEX LIMITED
CIN : L28129MH1984PLC032008
612, V.K.Industrial Estate, 10-14 Pais Street, Byculla (W), Mumbai 400 011.
Tel No. 022-23075677/23074585, **Fax No.** 022-23080022
Web: www.rishitechtext.com; **Email:** info@rishitechtext.com


EXTRACTS OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2025
(Rs. In Lakhs)

Particulars	Quarter Ended		Year Ended	
	30.06.2025	31.03.2025	30.06.2024	31.03.2025
	Unaudited	Audited	Unaudited	Audited
Total income from operations	3027.60	3558.05	2745.94	12562.23
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	92.66	137.93	54.51	337.66
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	92.66	137.93	54.51	337.66
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	65.43	107.57	39.19	229.94
Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	65.43	107.57	39.19	229.94
Equity Share Capital	739.10	739.10	739.10	739.10
Other Equity excluding Revaluation Reserve	-	2675.35	-	2675.35
Earnings Per Share (Face Value of Rs. 10/- each) (for continuing and discontinued operations):-				
Basic:	0.89	1.46	0.53	3.11
Diluted:	0.89	1.46	0.53	3.11

Notes:
1. The above is an extract of the detailed format of Unaudited Financial Results for the Quarter ended 30th June, 2025, filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015.
2. The above Unaudited financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meetings held on 5th August, 2025 and the Statutory Auditor has conducted limited review of the above financial results pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015.
3. The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
4. The previous period's figures have been regrouped / rearranged / reclassified wherever necessary.
5. The full format of the Financial Results are available on the stock exchange website and the website of the company i.e www.rishitechtext.com

For Rishi Techtex Limited
Sd/-
Abhishek Patel
(Managing Director)
DIN:05183410

Place : Mumbai
Date : 5th August, 2025



ALEMBIC PHARMACEUTICALS LIMITED
CIN: L24230GJ2010PLC061123
Regd. Office: Alembic Road, Vadodara - 390 003
Tel.: 0265 6637000
E-mail: apl.investors@alembic.co.in
Website: www.alembicpharmaceuticals.com

Extract of statement of Consolidated Unaudited Financial Results for the quarter ended 30th June, 2025
(₹ in Crores except per share data)


Particulars	Quarter Ended		Year Ended
	30.06.2025 (Unaudited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
Total Income from Operations	1,710.72	1,561.73	6,672.08
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	190.10	157.03	694.31
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	190.10	157.03	707.18
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	154.38	134.71	583.42
Total Comprehensive Income for the period	154.33	131.21	587.54
Equity Share Capital	39.31	39.31	39.31
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	—	—	5,151.63
Earning Per Share (Face Value of ₹2/- each) Basic & Diluted	7.85	6.84	29.68

Notes:

1. Standalone details


	Quarter Ended	Year Ended	
	30.06.2025 (Unaudited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
Income from Operations	1,494.17	1,475.56	6,032.63
Profit Before Tax	125.52	213.20	595.72
Profit After Tax	103.52	176.19	503.12

2. The above is an extract of the detailed format of the unaudited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at www.nseindia.com and www.bseindia.com and Company's website (URL: <https://alembicpharmaceuticals.com/quarterly-results>). The same can also be accessed by scanning the Quick Response (QR) Code provided below.



For Alembic Pharmaceuticals Limited
Sd/-
Chirayu Amin
Chairman and CEO


Place : Vadodara
Date : 5th August, 2025



Unaudited Standalone Financial Results for the third quarter / nine months ended 30 June 2025

The Board of Directors of Siemens Energy India Limited (“the Company”), based on the recommendations of the Audit Committee, at its meeting held on 04 August 2025, has approved the unaudited standalone financial results for the third quarter / nine months ended 30 June 2025, which have been subject to limited review by Price Waterhouse Chartered Accountants LLP, Statutory Auditors of the Company, in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The aforementioned financial results along with the limited review reports of the Statutory Auditors thereon are available on the website of the Company <https://www.siemens-energy-india.com/financial-results.html> and can also be accessed by scanning the Quick Response (QR) Code given below:



Place: Mumbai
Date: 04 August 2025

For Siemens Energy India Limited
Guilherme Vieira De Mendonca
Managing Director and Chief Executive Officer
DIN:09806385

Siemens Energy India Limited
Registered Office: Birla Aurora, Level 21, Plot No. 1080, Dr. Annie Besant Road, Worli, Mumbai - 400 030
Corporate Identity Number: L28110MH2024PLC418770
Tel: +91 22 6251 7000
E-mail: contact@siemens-energy-india.com
Website: www.siemens-energy-india.com



NITIN SPINNERS LIMITED
Regd. Office : 16-17 Km. Stone, Chittor Road, Hamirgarh, Bhilwara - 311 025 (Rajasthan)
CIN L17111RJ1992PLC006987 • Tel. : +91 1482 286110, Fax : 91 1482 286117
Website : www.nitinspinners.com • E-Mail : ns@nitinspinners.com

EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025
(Rs. in Lacs)


S. No.	Particulars	Quarter Ended		Year Ended	
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		Unaudited	Audited	Unaudited	Audited
1	Total Income from Operations (Net)	79509.26	84213.90	80440.14	330925.08
2	Net Profit / (Loss) for the period (before Tax, Exceptional items)	5512.70	6316.60	5692.11	23693.91
3	Net Profit / (Loss) for the period before Tax(after Exceptional items)	5512.70	6316.60	5692.11	23693.91
4	Net Profit / (Loss) for the period after Tax(after Exceptional items)	4098.63	4636.90	4211.68	17542.63
5	Total Comprehensive Income/(Loss) for the period [(Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income/(Loss) (after tax)]	3939.07	4963.99	4281.87	17892.63
6	Equity Share Capital (Face Value Rs. 10/- each)	5622.00	5622.00	5622.00	5622.00
7	Reserves i.e. Other Equity				125497.94
8	Earning Per Share (Rs. Per Shares) (of Rs. 10/- each) (for continuing and discontinued operations)-				
	1. Basic	7.29	8.25	7.49	31.20
	2. Diluted	7.29	8.25	7.49	31.20

Note:
The above is an extract of the detailed Financial Results for the Quarter ended 30th June, 2025 filed with the Stock Exchanges under regulation 33 of the SEBI (Listing and other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites www.bseindia.com, www.nseindia.com, Company's website www.nitinspinners.com and can be accessed by scanning QR Code given below.



For and on behalf of Board of Directors
For Nitin Spinners Ltd
(Dinesh Nolkha)
Chairman & Managing Director
DIN : 00054658

Date : 05-08-2025
Place : Hamirgarh (Bhilwara)



AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLC015190)
Regd. Office: Plot No.2, Maithrivi, Ameerpet, Hyderabad - 500 038, Telangana, India.
Tel: +91 400 23736370 Email: info@aurobindo.com


STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025
(All amounts are in ₹ millions, unless otherwise stated)

Sr. No.		Quarter Ended	Year Ended	Quarter Ended
		30.06.2025	31.03.2025	30.06.2024
		Unaudited	Audited	Unaudited
1	Total income from operations (net)	78,681.4	3,17,237.3	75,670.2
2	Profit before tax for the period	12,068.0	50,662.9	13,238.9
3	Profit after tax for the period	8,242.0	34,835.7	9,182.2
4	Total Comprehensive income for the period [Comprising Profit for the period (after tax) and Other Comprehensive income (after tax)]	12,300.4	37,871.9	8,771.7
5	Paid-up equity Share Capital (face value of ₹ 1/- each)	580.8	580.8	585.9
6	Other equity (excluding Revaluation Reserve) as shown in the unaudited financial results	-	-	-
7	Other equity (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	As on March 31, 2025 325,952.4		
8	Earnings per share of ₹ 1/- each	(Not annualised)	(Annualised)	(Not annualised)
	(a) Basic (in ₹)	14.20	59.81	15.69
	(b) Diluted (in ₹)	14.20	59.81	15.69

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025
(All amounts are in ₹ millions, unless otherwise stated)

Sr. No.		Quarter Ended	Year Ended	Quarter Ended
		30.06.2025	31.03.2025	30.06.2024
		Unaudited	Audited	Unaudited
1	Total income from operations (net)	28,481.7	1,09,333.0	24,600.9
2	Profit before tax for the period	7,500.9	23,584.5	4,462.4
3	Profit after tax for the period	5,591.3	17,467.9	3,290.4
4	Total Comprehensive income for the period [Comprising Profit for the period (after tax) and Other Comprehensive income (after tax)]	5,578.1	17,415.3	3,286.2
5	Paid-up equity Share Capital (face value of ₹ 1/- each)	580.8	580.8	585.9
6	Other equity (excluding Revaluation Reserve) as shown in the unaudited financial results	-	-	-
7	Other equity (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	As on March 31, 2025 204,760.3		
8	Earnings per share of ₹ 1/- each	(Not annualised)	(Annualised)	(Not annualised)
	(a) Basic (in ₹)	9.63	29.97	5.62
	(b) Diluted (in ₹)	9.63	29.97	5.62

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchanges' web sites viz. www.bseindia.com, www.nseindia.com and on the Company's web site viz. www.aurobindo.com and can also be accessed through the QR code given below.



By Order of the Board
Aurobindo Pharma Limited
Sd/-
K. Nithyananda Reddy
Vice Chairman & Managing Director

Place: Hyderabad
Date : August 4, 2025

www.aurobindo.com